罗格列酮对2型糖尿病患者支架内再狭窄作用的临床研究

摘要

Objective To observe the role of rosiglitazone in prevention of in-stent restenosis. Methods 72 CHD patients with T2DM undergoing selective stent implantation were selected from March to December 2009 in our department, and randomly divided into RGZ intervention group and control group. Plasma APN and ET were detected by ELISA before and 1,3,6 months after PCI operation. Data were statistically analyzed and the events of in-stent restensis were recorded. Results After 3 months, plasma APN levels was higher and serum Ins level was lower (all P<0. 05) in RGZ intervention group than in the control group. After 6 months, the plasma ET levels significantly reduced, FPG levels decreased significantly in RGZ group (all P<0. 05). Conclusions RGZ plays a role in prevention of in-stent restenosis by increasing plasma APN and decreasing plasma ET in CHD patients with T2DM after stent implantation.%目的 探讨胰岛素增敏剂罗格列酮(RGZ)干预支架内再狭窄(RS)的作用机制.方法 选取2009年3～12月我科收治的合并T2DM的冠心病(CHD)患者72例,均择期行选择性冠状动脉造影,必要时行支架安置术.术后随机分为RGZ干预组和Con组.术前和术后第1、3、6个月复查进行常规生化检测,ELISA测定血浆APN、内皮素(EIT)含量,统计学分析并记录患者RS事件的发生情况.结果 术后3个月,RGZ干预组较Con组血浆APN含量明显升高,血清Ins含量有所下降(P均<0.05);术后6个月,RGZ干预组较Con组血浆ET含量明显降低,FPG水平明显降低(P均<0.05).结论 RGZ可通过升高血浆APN、降低血浆ET含量,对合并T2DM的CHD患者术后RS起到一定的预防作用,其作用随着术后用药时间的延长逐渐显现.